| 1 |
Goldman CK, Bharara S, Palmer CA, et al. Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression[J]. Neurosurgery, 1997, 40: 1269-1277.
|
| 2 |
Shotaro M. The Endothelin ETB Receptor Antagonist BQ788 Protects against Brain Edema after Fluid Percussion Injury by Decreasing Vascular Endothelial Growth Factor-A Expression in Mice[J]. Yakugaku Zasshi, 2017, 137(10): 1241-1246.
|
| 3 |
Martin P, Jeeva M, Roger M, et al. Simulating vasogenic brain edema using chronic VEGF infusion[J]. J Neurosurg, 2017, 127(4): 905-916.
|
| 4 |
Nuh NR, Dmitriy K, Joao I, et al. Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases[J]. Sci Transl Med, 2016, 8(360): 360ra135.
|
| 5 |
Vaquero J, Zurita M, Oya S. Expression and significance of vascular permeability factor in tumour infiltrating lymphocytes of brain metastases[J]. Acta Neurochir (Wien), 2001, 143(2): 153-157.
|
| 6 |
Nassehi D. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain of edema[J]. Dan Med J, 2013, 60(4): B4626.
|
| 7 |
Zhou C, Wu YL, Chen GY, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase Ⅲ study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2015, 33(19): 2197-204.
|
| 8 |
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J]. N Engl J Med, 2006, 355(24): 2542-2550.
|
| 9 |
Shen G, Wang YJ, Guan YJ, et al. Relief effect of bevacizumab on severe edema induced by re-irradiation in brain tumor patients[J]. Chin Med J (Engl), 2015, 128(15): 2126-2129.
|
| 10 |
Ma YF, Zheng CT, Feng YP, et al. Bevacizumab for the Treatment of Gammaknife Radiosurgery-Induced Brain Radiation Necrosis[J]. J Craniofac Surg, 2017, 28(6): e569-e571.
|
| 11 |
Karen T, Herbert HE, Konstantin VS, et al. An analysis of radiation necrosis of the central nervous system treated with bevacizumab[J]. J Neurooncol, 2014, 117(2): 321-327.
|
| 12 |
Javier G, Ashok JK, Charles AC, et al. Effect of bevacizumab on radiation necrosis of the brain[J]. Int J Radiat Oncol Biol Phys, 2007, 67(2): 323-326.
|
| 13 |
Khasraw M, Holodny A, Goldlust SA, et al. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience[J]. Ann Oncol, 2012, 23(2): 458-463.
|
| 14 |
Meng XY, Zhao RG, Shen G, et al. Efficacy and safety of bevacizumab treatment for refractory brain edema: Case report[J]. Medicine (Baltimore), 2017, 96(44): e8280.
|
| 15 |
Martin R, Joachim von P, Petr Z, et al. Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL[J]. J Clin Oncol, 2009, 27(8): 1227-1234.
|
| 16 |
Jyoti DP, Mark AS, Edward BG, et al. Point Break: a randomized phase Ⅲ study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage ⅢB or Ⅳ nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2013, 31(34): 4349-4357.
|
| 17 |
Motohiro T, Akihiro T, Takayuki S, et al. Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations[J]. Invest New Drugs, 2018, 36(4): 608-614.
|
| 18 |
Matthew DH, Jamie EC, Valerie R, et al. Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab[J]. Cancer Chemother Pharmacol, 2013, 72(2): 453-461.
|